A cost analysis of hematopoietic colony-stimulating factors.


Journal Article

The administration of hematopoietic colony-stimulating factors (CSFs) to reduce the severity and duration of neutropenia associated with systemic chemotherapy has become widespread, although the appropriate use of these agents has not yet been fully defined. A cost model based on decision theory is presented for three therapeutic choices in these patients: no CSF, prophylactic CSF, and therapeutic CSF. Baseline probabilities were derived from a prospective, randomized, placebo-controlled trial of G-CSF in patients receiving systemic chemotherapy. Application of the model to institutionally generated cost figures provides comparative estimates of excess cost favoring the prophylactic use of CSFs. Model thresholds were calculated based on sensitivity analysis comparing no CSF to prophylactic CSF, and therapeutic CSF to prophylactic CSF. Guidelines are provided based on this model that are consistent with those adopted by the American Society of Clinical Oncology.

Full Text

Duke Authors

Cited Authors

  • Lyman, GH; Balducci, L

Published Date

  • November 1995

Published In

Volume / Issue

  • 9 / 11 Suppl

Start / End Page

  • 85 - 91

PubMed ID

  • 8608061

Pubmed Central ID

  • 8608061

International Standard Serial Number (ISSN)

  • 0890-9091


  • eng

Conference Location

  • United States